Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.

Human genomics - 28 Aug 2025

Yang Xiaodi, Liang Zeyin, Ji Li, Liu Wei, Wang Bingjie, Li Yuan, Ou Jinping, Cen Xinan, Ren Hanyun, Wuchty Stefan, Zhang Ziding, Dong Yujun

Abstract excerpt

While variant TP53 is an adverse prognosis factor in myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), current clinical prognosis and variation feature analysis of TP53 alterations remain limited. We evaluated 333 MDS/AML patients with TP53 mutations, single nucleotide polymorphisms (SNPs), and wild-type TP53 to characterize clinical features and identify prognostic factors using next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dioxygenases
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA-Binding Proteins

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Proto-Oncogene Proteins

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 40877983
DOI: 10.1186/s40246-025-00792-z
PMCID: PMC12395695

Genes

TP53
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative outcome and prognostic factor analysis among MDS/AML patients with TP53 mutations, snps, and wild type.PMID 40877983Read ↗

Variation characteristics and clinical significance of TP53 in patients with myeloid neoplasms.Semantic proximity Read ↗

TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantationSemantic proximity Read ↗

Genetic and Clinical Features in TP53-Mutated Patients With Myelodysplastic Neoplasms: A Retrospective Study Based on Next-Generation Sequencing Data.Semantic proximity Read ↗

TP53 in MDS and AML: Biological and clinical advances.Semantic proximity Read ↗

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.Semantic proximity Read ↗

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation.Semantic proximity Read ↗

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.Semantic proximity Read ↗

TP53 in AML and MDS: The new (old) kid on the block.Semantic proximity Read ↗

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasmsSemantic proximity Read ↗

Transplant for TP53-mutated MDS and AML: because we can or because we should?Semantic proximity Read ↗

Molecular and Clinical Insights into TP53-Mutated MDS and AML.Semantic proximity Read ↗

Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.